Publikationen

2012
Appenzeller S, Thier S, Papengut F, Klein C, Hagenah J, Kasten M, Berg D, Srulijes K, Gasser T, Schreiber S, Deuschl G, Kuhlenbäumer G. No association between NOD2 variants and Parkinson's disease. Mov Disord. 2012 Jul 13. [Epub ahead of print]

Appenzeller S, Thier S, Papengut F, Klein C, Hagenah J, Kasten M, Berg D, Srulijes K, Gasser T, Schreiber S, Deuschl G, Kuhlenbäumer G. No association between NOD2 variants and Parkinson's disease. Mov Disord. 2012 Jul 13. [Epub ahead of print]

Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, Gaenslen A, Huber H, Wurster I, Niebler R, Eschweiler GW, Berg D. Lowered Serum Amyloid-β1-42 Autoantibodies in Individuals with Lifetime Depression. J Alzheimers Dis. 2012 Jul 5. [Epub ahead of print]

Heinzel S, Metzger FG, Ehlis AC, Korell R, Alboji A, Haeussinger FB, Hagen K, Maetzler W, Eschweiler GW, Berg D, Fallgatter AJ; TREND Study Consortium. Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. Neurobiol Aging. 2012 Jul 5. [Epub ahead of print]

Brockmann K, Hilker R, Pilatus U, Baudrexel S, Srulijes K, Magerkurth J, Hauser AK, Schulte C, Csoti I, Merten CD, Gasser T, Berg D, Hattingen E. GBA-associated PD: Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology. 2012 Jul 17;79(3):213-20.

Roder C, Liu C, Schulte C, Kasuya H, Akagawa H, Nishizawa T, Yoneyama T, Okada Y, Khan N, Tatagiba M, Berg D, Krischek B. Analysis of TGFB1 in European and Japanese Moyamoya disease patients. Eur J Med Genet. 2012 May 31. [Epub ahead of print]

Synofzik M, Schicks J, Srulijes K, Schulte C, Schiele F, Berg D, Schöls L. POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study. J Neurol. 2012 May 12. [Epub ahead of print]

Synofzik M, Srulijes K, Godau J, Berg D, Schöls L. Characterizing POLG Ataxia: Clinics, Electrophysiology and Imaging. Cerebellum. 2012 Apr 12. [Epub ahead of print]

Berg D, Poewe W. Can we define "pre-motor" Parkinson's disease? Mov Disord. 2012 Apr 15;27(5):595-6.

Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies. Mov Disord. 2012 Apr 15;27(5):656-65.

Wachter B, Schürger S, Schmid A, Gröger A, Sadler R, Speidel A, Rolinger J, Pichler BJ, Berg D, Wagner HJ, von Ameln-Mayerhofer A, Küppers E. 6-Hydroxydopamine leads to T2 hyperintensity, decreased claudin-3 immunoreactivity and altered aquaporin 4 expression in the striatum. Behav Brain Res. 2012 Apr 10. [Epub ahead of print]

Weiss D, Brockmann K, Srulijes K, Meisner C, Klotz R, Reinbold S, Hauser AK, Schulte C, Berg D, Gasser T, Plewnia C, Gharabaghi A, Breit S, Wächter T, Krüger R. Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease. J Neurol. 2012 Mar 17. [Epub ahead of print]

Lill CM, Roehr JT, …, Berg D, …, Lehrach H, Ioannidis JP, Bertram L. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genet. 2012 Mar;8(3):e1002548.

Maetzler W, Mancini M, Liepelt-Scarfone I, Müller K, Becker C, van Lummel RC, Ainsworth E, Hobert M, Streffer J, Berg D, Chiari L. Impaired Trunk Stability in Individuals at High Risk for Parkinson’s Disease. PLoS One. 2012 Mar;7(3):e32240

Simon-Sanchez J., Kilarski LL., Nalls MA, Martinez M, Schulte C, Holmans P, International Parkinson’s Disease Genomics Consortium, Wellcome Trust Case Control Consortium, Gasser T, Hardy J, Singleton AB, Wood NW, Alexis
Brice A, Heutink P, Williams N, Morris HR. Cooperative Genome-Wide Analysis Shows Increased Homozygosity in Early Onset Parkinson’s Disease. PLoS One. 2012;7(3):e28787.

Saur R, Maier C, Milian M, Riedel E, Berg D, Liepelt-Scarfone I, Leyhe T. Clock Test Deficits related to the Global Cognitive State in Alzheimer’s and Parkinson’s Disease. Dement Geriatr Cogn Disorders 2012; 33:59-72.

Schmid SP, Schleicher ED, Cegan A, Deuschle C, Baur S, Hauser AK, Synofzik M, Srulijes K, Brockmann K, Berg D, Maetzler W. Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Mov Disord. 2012 Feb;27(2):288-93.

Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated α-Synuclein in Parkinson's Disease. Sci Transl Med. 2012 Feb 15;4(121):121ra20.

Srulijes K, Reimold M, Liscic RM, Bauer S, Dietzel E, Liepelt-Scarfone I, Berg D, Maetzler W. Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism. Mov Disord. 2012 Jan;27(1):151-5.

Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stöffler A, Streffer J, Berg D. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm. 2012 Jan;119(1):39-52.

Berg D. Is pre-motor diagnosis possible? - The European Experience. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S195-8.

Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, Gitler AD, Becker T, Weber M, Berg D, Andersen PM, Krüger R, Riess O, Ludolph AC, Auburger G. The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis. 2012 Jan;45(1):356-61.

2011
Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011 Dec;95(4):629-35.

Fernandes Rde C, Rosso AL, Vincent MB, Silva KS, Bonan C, Araújo NC, Berg D. Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. Arq Neuropsiquiatr. 2011 Dec;69(6):892-5.

van Es MA, Schelhaas HJ, …, Berg D, … van den Berg LH. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol. 2011 Dec;70(6):964-73.

Hobert MA, Niebler R, Meyer SI, Brockmann K, Becker C, Huber H, Gaenslen A, Godau J, Eschweiler GW, Berg D, Maetzler W. Poor Trail Making Test Performance Is Directly Associated with Altered Dual Task Prioritization in the Elderly - Baseline Results from the TREND Study. PLoS One. 2011;6(11):e27831. Epub 2011 Nov 16.

Balzer-Geldsetzer M, Ferreira Braga da Costa AS, Kronenbürger M, Schulz JB, Röske S, Spottke A, Wüllner U, Klockgether T, Storch A, Schneider C, Riedel O, Wittchen H-U, Seifried C, Hilker R, Schmidt N, Witt K, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Berg D, Gasser T, Kalbe E, Bodden M, Oertel WH, Dodel R. Parkinson’s Disease and Dementia: a Longitudinal Study (DEMPARK). Neuroepidemiology. 2011 Nov 4;37(3-4):168-176.

Brockmann K, Gröger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord. 2011 Nov;26(13):2335-42.

Sharma M, Maraganore DM, …, Gasser T, Krüger R, Genetic Epidemiology of Parkinson's Disease Consortium. Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiol Aging. 2011 Nov;32(11):2108.e1-5.

Ross OA, Soto-Ortolaza AI, Heckman MG, … Farrer MJ; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011 Oct;10(10):898-908.

Berg D. Tracking of striatal degeneration in prediagnostic Parkinson's disease: first steps into a promising future. Lancet Neurol. 2011 Sep;10(9):775-6.

Gröger A, Chadzynski G, Godau J, Berg D, Klose U. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol. 2011 Sep;21(9):1962-9.

Synofzik M, Godau J, Lindig T, Schöls L, Berg D. Transcranial Sonography Reveals Cerebellar, Nigral, and Forebrain Abnormalities in Friedreich's Ataxia. Neurodegener Dis. 2011;8(6):470-5.

Srulijes K, Mallien G, Bauer S, Dietzel E, Gröger A, Ebersbach G, Berg D, Maetzler W. In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. J Neural Transm. 2011 Aug;118(8):1191-7.

Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T, Berg D. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011 Jul 19;77(3):276-80.

Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W. Decreased α-Synuclein Serum Levels in Patients with Lewy Body Dementia Compared to Alzheimer's Disease Patients and Control Subjects. Dement Geriatr Cogn Disord. 2011 Jul 13;31(6):413-416.

Godau J, Knauel K, Weber K; Brockmann K, Maetzler W, Binder G, Berg D. Serum Insulinlike Growth Factor 1 as Possible Marker for Risk and Early Diagnosis of Parkinson Disease. Arch Neurol. 2011;68(7):925-931.

Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W. Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. A 37-Month 3-Center Study of 1847 Older Persons. Arch Neurol. 2011 Jul;68(7):932-7.

Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, Dillmann U, Gaenslen A, Di Santo A, Maetzler W, Berg D. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging. 2011;32:1599-1606.

International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2).A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 2011 Jun;7(6):e1002142. Epub 2011 Jun 30.

Höglinger GU, Melhem NM, Dickson DW, …Berg D, …Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jun 19;43(7):699-705.

Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B. AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Mov Disord. 2011 Jun;26(7):1243-50.

Guthoff M, Tschritter O, Berg D, Liepelt I, Schulte C, Machicao F, Breer H, Haering HU, Fritsche A. A polymorphism in the gene encoding AdipoR1 affects olfactory recognition. Int J Obes (Lond). 2011 Jun;35(6):873-6.

Fritz B, Rombach S, Godau J, Berg D, Horstmann T, Grau S. The influence of Nordic Walking training on sit-to-stand transfer in Parkinson patients. Gait Posture. 2011 Jun;34(2):234-8.

Berg D, Steinberger JD, Warren Olanow C, Naidich TP, Yousry TA. Milestones in magnetic resonance imaging and transcranial sonography of movement disorders. Mov Disord. 2011 May;26(6):979-92. doi: 10.1002/mds.23766.

Elbaz A, Ross OA, Ioannidis JP, …, Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol. 2011 May;69(5):778-92.

Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, …., Berg D, …., Winklhofer KF. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ. 2011 May;18(5):769-82.

Fischer MD, Synofzik M, Heidlauf R, Schicks J, Srulijes K, Kernstock C, Berg D, Schöls L, Schiefer U. Retinal nerve fiber layer loss in multiple system atrophy. Mov Disord. 2011 Apr;26(5):914-6.

Liepelt-Scarfone I, Gräber S, Feseker A, Baysal G, Godau J, Gaenslen A, Maetzler W, Berg D. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson’s disease. Parkinson’s Disease. Volume 2011 (2011), Article ID 540843, 7 pages, doi:10.4061/2011/540843.

Liepelt-Scarfone I, Behnke S, Godau J, Schweitzer KJ, Wolf B, Gaenslen A, Berg D. Relation of risk factors and putative premotor markers for Parkinson's disease. J Neural Transm. 2011 Apr;118(4):579-85.

Berg D. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm. 2011;118:613-619.

Fernández-Santiago R, Sharma M, Berg D, Illig T, Anneser J, Meyer T, Ludolph A, Gasser T. No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiol Aging. 2011 Mar;32(3):551.e1-4.

Roder C, Peters V, Kasuya H, Nishizawa T, Wakita S, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B. Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol. 2011 Mar;15(2):117-22.

Berg D. Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm. 2011 Mar;118(3):453-61.

Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. Mov Disord. 2011 Mar;26(4):653-8. doi: 10.1002/mds.23499.

Godau J, Berg D. Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases. Sleep Disorders, Vol. 2011, Article ID 468952, 6 pages, 2011. doi:10.1155/2011/468952.

Synofzik M, Godau J, Lindig T, Schöls L, Berg D. Restless Legs and Substantia Nigra Hypoechogenicity are Common Features in Friedreich's Ataxia. Cerebellum. 2011 Mar;10(1):9-13.

Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B. Common genetic polymorphisms in Moyamoya and Atherosclerotic Disease in Europeans. Childs Nerv Syst. 2011 Feb;27(2):245-52.

International Parkinson Disease Genomics Consortium. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011 Feb 19;377(9766):641-9.

Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M. Autoantibodies Against Amyloid and Glial-Derived Antigens are Increased in Serum and Cerebrospinal Fluid of Lewy Body-Associated Dementias. J Alzheimers Dis. 2011 Jan 1;26(1):171-9.

Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A , Gasser T, Berg D. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord. 2011 Jan;26(1):176-81.

Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, Wurster I, Schleicher E, Melms A, Berg D. Serum and Cerebrospinal Fluid Uric Acid Levels in Lewy Body Disorders: Associations with Disease Occurrence and Amyloid-β Pathway. J Alzheimers Dis. 2011 Jan 1;27(1):119-26.

Gräber S, Liepelt-Scarfone I, Brüssel T, Schweitzer K, Gasser T, Berg D. Self-estimated quality of life in monogenetic Parkinson's disease. Mov Disord. 2011 Jan;26(1):187-8.

2010
Godau J, Spinnler N, Wevers AK, Trenkwalder C, Berg D. Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1390-5.

Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B.Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien). 2010 Dec;152(12):2153-60.

Berg D, Godau J, Riederer P, Gerlach M, Arzberger T. Microglia activation is related to substantia nigra echogenicity. Journal of Neural Transmission. J Neural Transm. 2010 Nov;117(11):1287-92.

Wachter B, Schürger S, Rolinger J, von Ameln-Mayerhofer A, Berg D, Wagner HJ, Kueppers E.Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. Cell Tissue Res. 2010 Nov;342(2):147-60.

van de Loo S, Walter U, Behnke S, Hagenah J, Lorenz M, Sitzer M, Hilker R, Berg D. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1087-92.

Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, Brockmann K, Melms A, Gasser T, Berg D. Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-β42 Levels in Lewy Body Disease. J Alzheimers Dis. 2010 Jan 1;22(3):933-8.

Klebe S, Thier S, Lorenz D, Nothnagel M, Schreiber S, Klein C, Hagenah J, Kasten M, Berg D, Srulijes K, Gasser T, Deuschl G, Kuhlenbäumer G. LINGO1 is not associated with Parkinson's disease in German patients. Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1173-8.

Nicolai S, Mirelman A, Herman T, Zijlstra A, Mancini M, Becker C, Lindemann U, Berg D, Maetzler W. Improvement of balance after audio-biofeedback : A 6-week intervention study in patients with progressive supranuclear palsy. Z Gerontol Geriatr. 2010 Aug;43(4):224-8.

Maetzler W, Berg D, Funke C, Sandmann F, Stünitz H, Maetzler C, Nitsch C. Progressive Secondary Neurodegeneration and Microcalcification Co-Occur in Osteopontin-Deficient Mice. Am J Pathol. 2010 Aug;177(2):829-39.

Mänz C, Godau J, Berg D, Bender B, Ernemann U, Klose U. The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri. Neuroradiology. 2010 Aug;52(8):745-50.

Berg D, Gaenslen A. Place Value of Transcranial Sonography in Early Diagnosis of Parkinson's Disease. Neurodegener Dis. 2010;7(5):291-299.

Berg D, Seppi K, Liepelt I, Schweitzer K, Wollenweber F, Wolf B, Dillmann U, Stockner H, Godau J, Kiechl S, Gaenslen A, Willeit J, Di Santo A, Maetzler W, Gasser T, Poewe W, Behnke S. Enlarged Hyperechogenic Substantia Nigra Is Related to Motor Performance and Olfaction in the Elderly. Mov Disord. 2010 Jul 30;25(10):1464-9.

Berg D, Faust B. Therapiestrategien bei neu diagnostiziertem Parkinson. Neurologe & Psychiater. 2010; 6:56-58.

Soehn AS, Franck T, Biskup S, Giaime E, Melle C, Rott R, Cebo D, Kalbacher H, Ott E, Pahnke J, Meitinger T, Krüger R, Gasser T, Berg D, von Eggeling F, Engelender S, da Costa CA, Riess O. Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics. 2010 May;11(2):203-15.

Todd G, Taylor JL, Baumann D, Butler JE, Duma SR, Hayes M, Carew-Jones F, Piguet O, Behnke S, Ridding MC, Berg D, Double KL. Substantia nigra echomorphology and motor cortex excitability. Neuroimage. 2010 May 1;50(4):1351-1356.

Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 May;81(5):536-8.

Schweitzer KJ, Foroutan P, Dickson DW, Broderick DF, Klose U, Berg D, Wszolek ZK, Grant SC. A novel approach to dementia: high-resolution 1H MRI of the human hippocampus performed at 21.1 T. Neurology. 2010 May 18;74(20):1654.

Yasuno K, Bilguvar K, Bijlenga P, Low SK, ….Berg D, … Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet. 2010 May;42(5):420-5.

Pietzarka K, Reimann M, Schmidt C, Herting B, Schöls L, Reichmann H, Berg D, Schrader C, Ziemssen T. The cold hand sign in multiple system atrophy: skin perfusion revisited. J Neural Transm. 2010 Apr;117(4):475-9.

Subramanian T, Lieu CA, Guttalu K, Berg D. Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.Ultrasound Med Biol. 2010 Apr;36(4):604-9.

Woitalla D, Braak H, Tredici KD, Fogel W, Hagenah J, Oertel W, Berg D. Stellenwert der Hirnparenchym-Sonografie in der Differenzial- und Frühdiagnose des Parkinson-Syndroms. Fortschr Neurol Psychiatr. 2010 Mar;78 (Suppl 1):S25-30.

Walter U, Skoloudík D, Berg D. Transcranial sonography findings related to non-motor features of Parkinson's disease. J Neurol Sci. 2010 Feb 15; 289(1-2):123-7.

Godau J, Berg D. Role of transcranial ultrasound in the diagnosis of movement disorders. Neuroimaging Clin N Am. 2010 Feb;20(1):87-101.

Lindemann U, Nicolai S, Beische D, Becker C, Srulijes K, Dietzel E, Bauer S, Berg D, Maetzler W. Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. Mov Disord. 2010 Feb 3;25(8):1040-1046.

Friedrich C, Rüdiger H, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Berg D, Reichmann H, Ziemssen T. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. Mov Disord. 2010 Feb 15;25(3):315-24.

Liepelt I, Gaenslen A, Godau J, Di Santo A, Schweitzer KJ, Gasser T, Berg D. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010 Jan;6(1):70-4.

Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, Huber H, Brockmann K, Gasser T, Berg D, Melms A. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis. 2010 Jan;19(3):937-42.

Synofzik M, Asmus F, Reimold M, Schöls L, Berg D. Sustained dopaminergic response of Parkinsonism and depression in POLG-associated Parkinsonism. Mov Disord. 2010 Jan 30;25(2):243-5.

Günther A, Berg D, Joachimski F, Ragoschke-Schumm A, Redecker C. Neurological picture. Acute Wernicke's encephalopathy with hyperechogenic corpora mammillaria in brain sonography. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):114-5.

Reimann M, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schoels L, Reichmann H, Berg D, Ziemssen T. Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm. 2010 Jan;117(1):69-76.

Evangelou E, Maraganore DM, Annesi G, ........ Berg D, …..Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: Large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):220-8.

Lücking CB, Lichtner P, Kramer ER, Gieger C, Illig T, Dichgans M, Berg D, Gasser T. Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany. Neurobiol Aging. 2010 Jan;31(1):167-8.

2009
Berg D. Transcranial ultrasound as a risk marker for Parkinson’s disease. Mov Disord. 2009, 24 Suppl 2:S677-83.

Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009 Dec;8(12):1158-71.

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61.

Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C,et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009 Dec;41(12):1308-12.

Schmidt C, Berg D; Herting, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Ziemssen T. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009 Oct 30;24(14):2136-42.

Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord. 2009 Oct 30;24(14):2104-11.

Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wüllner U, Illig T, Sharma M, Gasser T. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging. 2009 May; 30(5):731-8.

Funke C, Soehn AS, Tomiuk J, Riess O, Berg D. Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm. 2009 Apr;116(4):443-50.

Funke C, Tomiuk J, Riess O, Berg D, Soehn AS. Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. J Neural Transm. 2009 Jul;116(7):853-9.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, Ziemssen T. Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm. 2009 Jul;116(7):875-80.

Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage. 2009 Oct 1;47(4):1237-43.

Guthoff M, Tschritter O, Berg D, Liepelt I, Schulte C, Machicao F, Haering HU, Fritsche A. Effect of genetic variation in Kv1.3 on olfactory function. Diabetes Metab Res Rev. 2009 Sep;25(6):523-7.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, Herbst H, Berg D. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[(18)F]FDG-PET. Mov Disord. 2009 Jul 30;24(10):1504-11.

Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord. 2009 Aug;15(7):539-41.

Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T, Schulte C, Berg D. A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm. 2009 May;116(5):599-605.

Fernández-Santiago R, Hoenig S, Lichtner P, Sperfeld AD, Sharma M, Berg D, Weichenrieder O, Illig T, Eger K, Meyer T, Anneser J, Münch C, Zierz S, Gasser T, Ludolph A. Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol. 2009 Aug;256(8):1337-42.

Sharma M, Lichtner P, Kruger R, Berg D, Schulte C, Illig T, Riess O, Gasser T. Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging. 2009 Oct;30(10):1706-9.

Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009 May;65(5):610-4.

Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis. 2009 Aug;35(2):296-301.

Rothfuss O, Fischer H, Hasegawa T, Maisel M, Leitner P, Miesel F, Sharma M, Bornemann A, Berg D, Gasser T, Patenge N. Parkin protects Mitochondrial Genome Integrity and supports Mitochondrial DNA Repair. Hum Mol Genet. 2009 Oct 15;18(20):3832-50.

Godau J, Manz A, Wevers AK, Gaenslen A, Berg D. Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Mov Disord. 2009 Jan 15;24(1):133-7.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009 Apr;34(1):107-12.

2008
Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Reichmann H, Berg D, Ziemssen T.Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord. 2008 Oct 30;23(14):2083-9.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, Ziemssen T. Autonomic dysfunction in different subtypes of multiple system atrophy. Mov Disord. 2008 Sep 15;23(12):1766-72.
Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008 Nov;7(11):1044-55.

Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T.Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008 May;22(5):1327-34.

Kamm C, Fogel W, Wächter T, Schweitzer K, Berg D, Kruger R, Freudenstein D, Gasser T. Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. Neurology. 2008 Apr 15;70(16 Pt 2):1501-3.

Schroeder C, Walter M, Berg D, Leitner P, Bauer P, Kohl Z, Winkler J, Riess O, Bonin M. High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease. J Mol Diagn. 2008 May;10(3):217-24.

Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis. 2008;5:133-6.

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla H.-J., Reimold M, Marek K, Berg D. Prospective evaluation of the specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease. Lancet Neurol. 2008 May;7(5):417-24.

Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome, Mov Disord. 2008 Jun 15;23(8):1184-7.

Liepelt I, Wendt A, Schweitzer K.J., Wolf B, Godau J, Gaenslen A, Bruessel T, Berg D. Substantia nigra hyperechogenicity assessed by Transcranial Sonography is related to neuropsychological impairment in the elderly population. J Neural Transm. 2008 Jul;115(7):993-9.

Unger MM, Möller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, Hoeffken H, Mayer G, Oertel WH. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord. 2008 Mar 15;23(4):596-9.

Lücking CB, Lichtner P, Dichgans M, Illig T, Gieger C, Berg D, Gasser T. Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease. J Neurol. 2008 Mar;255(3):441-2.

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008 Apr 15;70(16 Pt 2):1456-60.

Prestel J, Gempel K, Hauser TK, Schweitzer K, Prokisch H, Ahting U, Freudenstein D, Bueltmann E, Naegele T, Berg D, Klopstock T, Gasser T. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol. 2008 May;255(5):643-8.

Gaenslen A, Gasser T, Berg D. Nutrition and the risk for Parkinson's disease: review of the literature. J Neural Transm. 2008 115(5):703-13.

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-33.

Godau J, Wevers AK, Gaenslen A, Di Santo A, Liepelt I, Gasser T, Berg D. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med. 2008 Oct;9(7):782-9.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment for dementia in parkinsonian syndromes: Efficacy of cholinesterase inhibitors. Nervenarzt. 2008; 79:36-46.